Emerging technologies such as AI, next generation sequencing and display systems are changing the way antibodies are being engineered at a rapid rate. At the same time, novel approaches to identifying targets and delivering antibodies are improving therapeutic effectiveness. However, there are still plenty of challenges that need to be overcome.
The Antibody Engineering & Therapeutics conference series recently (Aug 2019) conducted a survey of industry professionals from pharma, biotechs, academia, CDMOs, CROs, service providers and consultancies around the world. This report based on 211 responses reveals unique insights into the hottest potential opportunities and the biggest challenges around emerging technologies and novel approaches in antibody engineering and therapeutics.
